The largest pharmaceutical companies in Europe faced the President of the European Commission, Ursula von der Lin yesterday, as Donald Trump promised an imminent arrival of definitions on American drug imports.

Trump told the guests of the National Congress of Republican Committee on Tuesday that the White House would announce a “big tariff” on pharmaceutical imports “very soon” to applaud the party crowd.

“We will define our medications, and once you do this, they will return to our country because we are a big market.

“Something sells $ 88 in London selling $ 1300 here, made in the same factory by the same company.

Trump predicted that as soon as these definitions become valid, drug groups will quickly leave their manufacturing rules outside the United States and build factories in the states.

The US President obtained a help in the transfer of this message to one of the main nemeses, the European Union, from the mass pharmaceutical companies.

Pharmaceutors in Europe face the European Union

The European Union for Industries and Pharmaceutical Societies (EFPIA), the lobby group that represents the largest drug makers in Europe, went to the European Commission (EC) yesterday to hold talks with Von Der Leyen, and calls for radical change and suspending the threat of the migration of the United States at the head of the European Papers.

“Today, the executive directors of the research -based pharmaceutical industry issued a blatant warning to President von der Lin that unless Europe changes the quick and radical policy, it is likely that pharmaceutical research and manufacturing will be directed to the United States,” the president, whose president, Novo Nordesk Fruegard Georgard, will be directed to the United States. He said in a statement.

Novo Nordisk representatives, Novartis, Sanofi, and Bayer were all in the talks.

The Lobby Group said that 103.2 billion euros (113.8 billion dollars) of capital, research and development investment plans were at risk of not fulfilling in Europe as the uncertainty.

“The United States is now leading Europe on every investor scale of capital, intellectual property and speedy approval of innovation.

“In addition to the uncertainty resulting from the threat of definitions, there are few incentives to invest in the European Union and important drivers to move to the United States.”

The European Union has shipped medical and pharmaceutical products worth 92 billion euros (100 billion dollars) to the United States in 2023 The history of Eurostat. The major American pharmaceutical companies, including Pfizer and Johnson & Johnson, are manufacturing many of their drugs in Europe before exporting to the United States that Trump wants to re -manufacture these companies with the temptation of foreign producers on American beaches.

EFPIA said that the European Union needs to make progress in competitiveness and enhance the provisions of intellectual property, as well as create a global leading organizational framework.

“Participants emphasized the strategic value of this sector of the European Union. They have sparked strong concerns about the extensive repercussions of the American definitions, which would harm the two side of the Atlantic Ocean, with repercussions on the global interconnected supply chains and the availability of medicines for European patients and the United States alike,“ a ” statement From the committee reading.

The stocks fell to the largest pharmaceutical makers in Europe in the early morning, as investors made Trump’s remarks on Tuesday.

Novartis shares decreased by 6.5 % by 11 am Central European time, while Sanofi shares decreased by more than 5 %.

Novo Nordisk shares decreased by 4 %. The value of the Danish pharmaceutical maker has now returned to where it was in late 2022.

This story was originally shown on Fortune.com

https://fortune.com/img-assets/wp-content/uploads/2025/04/1694684688663-1-e1744193781360.jpeg?resize=1200,600
2025-04-09 10:26:00